Protara Therapeutics (TARA) to Release Earnings on Wednesday

Protara Therapeutics (NASDAQ:TARA) is projected to release its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect Protara Therapeutics to post earnings of ($0.34) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 9, 2026 at 9:30 AM ET.

Protara Therapeutics Price Performance

NASDAQ:TARA opened at $6.36 on Monday. The company has a 50 day moving average price of $6.02 and a 200-day moving average price of $5.21. Protara Therapeutics has a 1-year low of $2.77 and a 1-year high of $7.82. The firm has a market cap of $328.37 million, a price-to-earnings ratio of -4.45 and a beta of 1.40.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on TARA. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Protara Therapeutics in a report on Tuesday, February 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Thursday, January 22nd. Finally, Piper Sandler assumed coverage on Protara Therapeutics in a report on Wednesday, January 7th. They issued an “overweight” rating and a $24.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.40.

Institutional Trading of Protara Therapeutics

A number of institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. purchased a new stake in shares of Protara Therapeutics during the second quarter worth approximately $46,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Protara Therapeutics during the 2nd quarter worth $53,000. Persistent Asset Partners Ltd acquired a new stake in Protara Therapeutics during the 4th quarter worth $57,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Protara Therapeutics during the fourth quarter worth $59,000. Finally, Invesco Ltd. acquired a new stake in shares of Protara Therapeutics in the second quarter valued at about $73,000. 38.13% of the stock is owned by institutional investors and hedge funds.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.